Type 2 diabetes mellitus (T2DM) is a major public health challenge in India, with an estimated 101 million individuals ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based ...

The study found that some people taking SGLT2 inhibitors developed a dangerous infection called Fournier gangrene. This ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

For a disease afflicting 35.5 million people in the U.S., chronic kidney disease flies under the radar. Only half the people ...

The following is a summary of “YouTube as a source of information for stroke rehabilitation: a cross-sectional analysis of ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...